Antibody Engineering

The Masonic Cancer Center’s Antibody Engineering Shared Resource (AESR) (developing) provides expertise and infrastructure for the discovery, optimization, and pre-clinical development of next-generation protein-based therapeutics. The AESHR team takes biomolecular targets identified by clients and develops tailored antibodies and protein binding agents to meet research and clinical objectives. Our goal is to transform initial discovery concepts into high-quality materials ready for pre-clinical testing in client laboratories.

Services provided by AESHR integrate traditional approaches in recombinant protein biochemistry with state-of-the-art computational design in a high-throughput discovery pipeline. Key technologies include yeast and phage display of antibody libraries, lead identification using next-generation DNA sequencing, and lead optimization using AI-guided molecular modeling and machine learning. Synergy between bench and computational technologies enables the identification of potent and selective antibody candidates for use in cancer immunotherapies including antibody-drug conjugates, bispecific antibodies, antibody-cytokine fusions proteins, and chimeric antigen receptor cells.